Compare UFI & LONA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UFI | LONA |
|---|---|---|
| Founded | 1969 | 2011 |
| Country | United States | United States |
| Employees | N/A | 19 |
| Industry | Textiles | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 76.4M | 81.5M |
| IPO Year | 1994 | N/A |
| Metric | UFI | LONA |
|---|---|---|
| Price | $6.04 | $9.77 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | ★ 100.7K | 34.7K |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $571,344,000.00 | N/A |
| Revenue This Year | $1.39 | N/A |
| Revenue Next Year | $12.57 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.96 | $4.21 |
| 52 Week High | $6.23 | $14.21 |
| Indicator | UFI | LONA |
|---|---|---|
| Relative Strength Index (RSI) | 87.26 | 61.08 |
| Support Level | $3.72 | $8.06 |
| Resistance Level | N/A | $11.44 |
| Average True Range (ATR) | 0.30 | 0.73 |
| MACD | 0.14 | 0.16 |
| Stochastic Oscillator | 96.84 | 87.73 |
Unifi Inc is a multi-national company. It manufactures and sells synthetic and recycled products made from polyester and nylon predominantly to other yarn manufacturers and knitters and weavers that produce fabric for apparel, hosiery, home furnishings, automotive, industrial, and other end-use markets. Polyester yarns include partially oriented yarn (POY), textured, solution and package dyed, twisted, beamed, and draw wound yarns, and each is available in virgin or recycled varieties. UNIFI offers specialized yarns, premium value-added (PVA) yarns, and commodity yarns. The company's reportable segments are; the Americas, Brazil, and Asia. Its maximum revenue is derived from the Americas.
LeonaBio Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for high unmet medical needs. Its key drug candidates, lasofoxifene and ATH-1105, are novel, small-molecule therapies with the potential to address treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS). LeonaBio is also exploring the use of other drug candidates that enhance the neurotrophic HGF system, including ATH-1020, to improve neuronal health and function in multiple neurological diseases. In addition, it is also focused on designing and testing new early compounds directed towards novel targets for a variety of clinical applications. The company operates as a single operating segment, developing and commercializing therapeutics.